Omeros (NASDAQ:OMER) Releases Q1 2024 Earnings Guidance

Omeros (NASDAQ:OMER) updated its first quarter 2024 earnings guidance on Monday. The company provided EPS guidance of -0.630–0.580 for the period. The company issued revenue guidance of -.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Omeros from a hold rating to a sell rating in a research note on Tuesday, March 26th.

Omeros Trading Down 7.5 %

Shares of NASDAQ:OMER traded down $0.26 during trading on Monday, reaching $3.19. The company had a trading volume of 548,783 shares, compared to its average volume of 592,561. The company has a fifty day moving average of $3.88 and a two-hundred day moving average of $2.97. The stock has a market capitalization of $200.56 million, a P/E ratio of 9.97 and a beta of 1.34. Omeros has a 12 month low of $0.92 and a 12 month high of $7.80.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in shares of Omeros by 258.0% in the 2nd quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company’s stock worth $22,603,000 after buying an additional 2,994,468 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Omeros by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company’s stock worth $20,642,000 after buying an additional 76,869 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Omeros by 4.7% in the 2nd quarter. Stifel Financial Corp now owns 2,056,835 shares of the biopharmaceutical company’s stock worth $11,189,000 after buying an additional 93,215 shares during the last quarter. State Street Corp increased its holdings in shares of Omeros by 2.8% in the 1st quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical company’s stock worth $8,490,000 after buying an additional 38,498 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Omeros by 98.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company’s stock valued at $6,820,000 after purchasing an additional 621,819 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.